WHO cares. It’s now time you did The old adage tells us not to fix things the things that aren’t broken. Logic suggests, therefore, that wherever we do see a fix being applied, we can safely assume things aren’t working … Read More
clinical trials
WHO Cares: A pro-adherence strategy means little without the drive for better data quality
When a high-profile authority in the medical world such as the World Health Organization’s publishes guidelines governing best practice in clinical trials, the sector takes note. Reading the guidelines, many will have welcomed WHO’s aims to “reform, improve and streamline” … Read More
From Sealed Envelopes to Smart Adherence: Why Clinical Trials Must Embrace Digital Innovation
Nostalgia can trick us into thinking that things were better in the “good old days”. But the world of science is rarely a place where sentimentality should cloud better judgement. Rather, it is a place where questions, analysis and evidence … Read More
Protecting your investment: How clinical trial failings are costing the investor community
When bringing a new drug product to market, powerful motivating forces are involved. And while the potential for enhancing, or even extending, the lives of patients unquestionably takes primacy, there is another inescapably influential factor in the mix: profitability. For … Read More
Dose reduction’s role in tackling Pharma 2.0’s profitability problem
The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside … Read More
One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies
In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and … Read More
The Importance of Dose Optimisation in Oncology Clinical Trials
Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new cases of cancer worldwide in 2020, with around 10 million … Read More
Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare … Read More
AARDEX and Schreiner MediPharm reinforce their collaboration to Enhance Medication Adherence Management
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More